— medmix at a glance — Our key figures
Our key figures
Our revenue was CHF 248.1 million, a decrease of 1.0% (increase 2.2% currency-adjusted, increase 1.3% organic), compared with H1 2022. We delivered an adjusted EBITDA margin of 20.0% and free cash flow of CHF –4.9 million.
Share of revenue by market segment
H1 2023
Share of revenue by market segment
H1 2022
Key figures
January 1 – June 30
|
millions of CHF |
|
2023 |
|
2022 1) |
|
Change in +/–% |
|
+/–% adjusted 2) |
|
+/–% organic 3) |
|
Revenue |
|
248.1 |
|
250.6 |
|
–1.0 |
|
2.2 |
|
1.3 |
|
Gross profit |
|
82.0 |
|
99.2 |
|
–17.3 |
|
|
|
|
|
Operating income (EBIT) |
|
14.5 |
|
16.9 |
|
–14.5 |
|
|
|
|
|
EBITDA |
|
40.0 |
|
41.7 |
|
–4.0 |
|
|
|
|
|
Adjusted EBITDA |
|
49.7 |
|
60.1 |
|
–17.3 |
|
|
|
|
|
Adjusted EBITDA margin |
|
20.0% |
|
24.0% |
|
|
|
|
|
|
|
Net income attributable to shareholders of medmix Ltd |
|
7.3 |
|
9.2 |
|
–21.3 |
|
|
|
|
|
Basic earnings per share (in CHF) |
|
0.18 |
|
0.23 |
|
–21.1 |
|
|
|
|
|
Free cash flow (FCF) |
|
–4.9 |
|
14.2 |
|
n/a |
|
|
|
|
|
Net debt as of June 30 / December 31 |
|
164.0 |
|
156.7 |
|
4.7 |
|
|
|
|
|
Net debt adjusted EBITDA ratio as of June 30 / December 31 4) |
|
1.73 |
|
1.49 |
|
16.1 |
|
|
|
|
|
Employees (number of full-time equivalents) as of June 30 / December 31 |
|
2’245 |
|
2’067 |
|
8.6 |
|
|
|
|
1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.
2) Adjusted for currency effects.
3) Adjusted for acquisition and currency effects.
4) Adjusted EBITDA for the last 12 months
Our Key figures
revenue in H1 2023
adjusted EBITDA margin
free cash flow generated in H1 2023